Insuman Rapid

Insulin human, the active ingredient in Insuman Rapid, is a insulin presented as a 100 IU/mL solution for injection for subcutaneous use. Its rapid onset of action helps control post‑prandial glucose spikes and it treats hyperglycemia in patients with type 1 and type 2 diabetes mellitus. The product is manufactured in the European Union and meets EU pharmacopoeial standards.

GNH USA supplies Insuman Rapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Rapid, a rapid‑acting insulin, is used to control blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: provides rapid glucose lowering after meals to achieve post‑prandial targets. - Type 2 diabetes mellitus: assists in achieving post‑prandial glycemic control as part of a basal‑bolus regimen. - Management of hyperglycemia: reduces elevated blood glucose levels promptly. - Diabetic ketoacidosis: used as part of insulin therapy to correct metabolic derangements.

Common Side Effects: - Hypoglycemia: low blood glucose levels causing dizziness, sweating, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat tissue. - Allergic rash: mild skin eruptions. - Edema: mild fluid retention.

Serious or Rare Side Effects: - Severe hypoglycemia: can lead to loss of consciousness or seizures. - Anaphylaxis: rare systemic allergic reaction requiring emergency care. - Systemic insulin allergy: widespread urticaria or angioedema. - Hypokalemia: low potassium levels, especially with high insulin doses. - Severe edema: significant fluid accumulation. - Urticaria: persistent hives beyond the injection site.

Patients and healthcare providers should consider the following precautions when using Insuman Rapid.

- Dose adjustment: monitor blood glucose regularly and adjust dose as needed. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose. - Renal impairment: may require dose modification due to altered insulin clearance. - Pregnancy: use only if benefits outweigh potential risks; classified as Category B. - Concomitant medications: assess interactions with other glucose‑lowering agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Rapid may interact with other medicines; careful management is required.

Major Interactions (Avoid): - Sulfonylureas: increased risk of severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - MAO inhibitors: unpredictable effects on glucose control. - Alcohol: can potentiate hypoglycemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose levels. - Corticosteroids: can increase glucose concentrations. - ACE inhibitors: may affect potassium balance. - Other insulin analogs: may require dose adjustments when used together.